scholarly journals Conspicuity and imaging features of breast cancers on digital breast tomosynthesis according to molecular profile

Author(s):  
Léa Manse ◽  
Martine Boisserie-Lacroix ◽  
Véronique Brouste ◽  
Marie-Pierre Depetiteville ◽  
Benoît Mesurolle ◽  
...  

Abstract Objective To describe BI-RADS features and evaluate conspicuity of breast cancer on digital breast tomosynthesis (DBT) according to their molecular profile. Materials and method Institutional review board was obtained for this retrospective study. Consecutive patients with histologically proven breast cancers who underwent digital breast tomosynthesis (DBT) with 2D synthetic mammography (SM) and digital mammography (DM) at the time of diagnosis were included. Morphological features and conspicuity of cancers on DM, SM and DBT were evaluated in consensus by two breast radiologists. Imaging features were compared across molecular subtypes (luminal, triple negative (TN) and HER2+) using Fisher’s exact test and between DBT and SM and DM using McNemar’s test. Conspicuity was compared between DBT and SM and DM using Wilcoxon matched pairs test and between each molecular subtype using the Wilcoxon test. Results One hundred and eleven consecutive patients were included. On DBT, TN cancers more frequently presented as masses with microlobulated margins (P = 0.04) while HER2 + cancers were more often associated with microcalcifications (P = 0.02). Greater conspicuity on DBT in comparison to DM was observed for cancers with low Ki67 (P = .015), less aggressive tumours (P = .005), positive ER (P = 0.005), positive PR (P = .005) or negative HER2 (P = .024), and for luminal molecular profiles (P = 0.012) while no difference was observed between the two techniques for TN (P = .73) and HER+ (P = .79) tumours. Conclusion DBT reveals specific features of breast cancers according to their molecular characteristics. In comparison with DM, DBT improves conspicuity of luminal subtype cancers and tumours demonstrating less aggressive features on pathology.

2017 ◽  
Vol 209 (6) ◽  
pp. 1411-1418 ◽  
Author(s):  
Jin You Kim ◽  
Hyun Jung Kang ◽  
Jong Ki Shin ◽  
Nam Kyung Lee ◽  
You Seon Song ◽  
...  

Radiographics ◽  
2019 ◽  
Vol 39 (2) ◽  
pp. 307-318 ◽  
Author(s):  
Joao V. Horvat ◽  
Delia M. Keating ◽  
Halio Rodrigues-Duarte ◽  
Elizabeth A. Morris ◽  
Victoria L. Mango

ESMO Open ◽  
2020 ◽  
Vol 5 (6) ◽  
pp. e000942
Author(s):  
Andreas Seeber ◽  
Kai Zimmer ◽  
Florian Kocher ◽  
Alberto Puccini ◽  
Joanne Xiu ◽  
...  

IntroductionPoly-(ADP)-ribose polymerase (PARP) inhibitors are successfully used for treatment of BRCA-mutated (mut) breast cancers and are under extensive evaluation for BRCA- and PALB2-mutated pancreatic ductal adenocarcinoma (PDAC). However, the optimal treatment regimen for BRCA/PALB2-mutated PDCA has yet to be established. Moreover, limited data are available on the association of BRCA/PALB2 gene alterations with other comutations and immunological biomarkers.Material and methodsTumour samples of 2818 patients with PDAC were analysed for BRCA1/2 PALB2 mutations and other genes by next-generation sequencing (NGS) (MiSeq on 47 genes, NextSeq on 592 genes). TMB was calculated based on somatic non-synonymous missense mutations. MSI-H/dMMR was evaluated by NGS, and PD-L1 expression was determined using immunohistochemistry.ResultsIn 4.2% (n=124) of all PDAC samples BRCA mutations have been detected. BRCA2 mutations were more commonly observed than BRCA1 mutations (3.1%(n=89) vs 1.1% [n=35], p<0.0001). BRCA2 mutation was associated with an older age (64 vs 61 years for wild-type (wt), p=0.002) and PALB2 mutation was observed more frequently in female than in male patients. BRCA and PALB2 mutations were associated with MSI-H/dMMR compared with wt (BRCA: 4.8% vs 1.2%, p=0.002; PALB2: 6.7% vs 1.3 %, p=0.18), PD-L1 expression of >1.0% (BRCA: 21.8% vs wt 11.2%, p<0.001, PALB2: 0.0% vs 12.4 %, p=0.38) and high TMB (BRCA: mean 8.7 vs 6.5 mut/MB, p<0.001; PALB2: 10.6 mut/Mb vs 6.6 mut/Mb, p=0.0007). Also, PD-L1 expression and TMB differed between BRCA and PALB2 mutation and wt samples in MSS tumours (p<0.05). BRCA-mutated and PALB2-mutated PDACs were characterised by a different mutational profile than was observed in wt tumours.ConclusionsBRCA and PALB2 mutations were found in a significant subgroup of PDACs. These mutations were associated with a distinct molecular profile potentially predictive for response to immune-checkpoint inhibitor therapy. Therefore, these data provide a rationale to evaluate PARP inhibitors in combination with immune-checkpoint inhibitors in patients with BRCA/PALB2-mutated PDAC.


The Breast ◽  
2015 ◽  
Vol 24 (5) ◽  
pp. 649-655 ◽  
Author(s):  
Kyung Jin Nam ◽  
Boo-Kyung Han ◽  
Eun Sook Ko ◽  
Ji Soo Choi ◽  
Eun Young Ko ◽  
...  

Breast Cancer ◽  
2015 ◽  
Vol 23 (6) ◽  
pp. 886-892 ◽  
Author(s):  
Woo Jung Choi ◽  
Hak Hee Kim ◽  
Sun Young Lee ◽  
Eun Young Chae ◽  
Hee Jung Shin ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document